Browsing by Author "Songsak Petmitr"
Now showing 1 - 4 of 4
Results Per Page
Sort Options
Item Histological type of intrahepatic cholangiocarcinoma differentiated by genetic alteration from AP-PCR fingerprint(Asian Pacific Organization for Cancer Prevention, 2011) Ubol Chuensumran; Pensri Saelee; Sopit Wongkham; Chawalit Pairojkul; Siri Chauin; Songsak Petmitr; U. Chuensumran; Department of Chemistry, Faculty of Science and Technology, Rajabhat University Suan Dusit, Bangkok, Thailand; email: ubolc@yahoo.comCholangiocarcinoma (CCA), the malignant neoplasm of the biliary epithelium, is usually fatal due to difficulty in early diagnosis and lack of availability of effective therapy. The genetic mechanisms involved in the development of CCA are not well understood and only a few cytogenetic studies have been published. In this study, genomic instability in 30 Thai cases of intrahepatic cholangiocarcinoma (ICC) was assessed using an arbitrarily primed- polymerase chain reaction (AP-PCR) method. Genetic alterations were analyzed as banding pattern changes between tumors and corresponding normal DNA. The abnormal band present at the highest frequency (23/30 cases, 77%) appeared with the AO16 primer. Statistical analysis also showed that DNA alteration from this primer was significantly associated with the moderately to poorly differentiated histological type (P = 0.038). Kaplan-Meier survival curves showed borderline significance for this DNA aberration (P = 0.06 by the log-rank test). This DNA fragment may thus be of use to predict degree of malignancy of the disease.Item Hypermethylation of suppressor of cytokine signaling 1 in hepatocellular carcinoma patients(Asian Pacific Organization for Cancer Prevention, 2012) Pensri Saelee; Ubol Chuensumran; Sopit Wongkham; Sunanta Chariyalertsak; Danai Tiwawech; Songsak Petmitr; P. Saelee; Research Division, National Cancer Institute, Bangkok, Thailand; email: saelee@health.moph.go.thHepatocellular carcinoma (HCC), the most common primary hepatic tumor, is highly prevalent in the Asia-Pacific region, including Thailand. Many genetic and epigenetic alterations in HCC have been elucidated. The aim of this study was to determine whether aberrant methylation of the suppressor of cytokine signaling 1 gene (SOCS1) occurs in HCCs. Methylation specific-PCR assays were performed to identify the methylation status of SOCS1 in 29 tumors and their corresponding normal liver tissues. An abnormal methylation status was detected in 17 (59%), with a higher prevalence of aberrant SOCS1 methylation significantly correlating with HCC treated without chemotherapy (OR=0.04, 95%CI=0.01-0.31; P=0.001). This study suggests that epigenetic aberrant SOCS1 methylation may be a predictive marker for HCC patients.Item RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma(Asian Pacific Organization for Cancer Prevention, 2010) Pensri Saelee; Sopit Wongkham; Sunanta Chariyalertsak; Songsak Petmitr; Ubol Chuensumran; P. Saelee; Research Division, National Cancer Institute, Bangkok, Thailand; email: saelee@health.moph.go.thThis study was performed to determine whether epigenetic aberrant methylation of RASSF1A might be associated with hepatocarcinogenesis. Methylation specific-PCR was performed to identify RASSF1A promoter hypermethylation in 29 tumors and corresponding normal liver tissues. In addition, RASSF1A mRNA levels were analyzed by quantitative real-time reverse transcription-PCR. Aberrant methylation of RASSF1A was detected in 25 of 29 cases (86%), with loss of RASSF1A expression evident in 8 of 22 cases (36%). No correlation between loss of RASSF1A mRNA and promoter hypermethylation of the RASSF1A gene was observed. There was a significant correlation between the methylation status of RASSF1A and hepatocellular carcinoma (HCC) patients who did not undergo chemotherapy (P = 0.03). Multivariate analysis, adjusted for tumor size, treatment, RASSF1A hypermethylation, and RASSF1A under-expression, showed RASSF1A hypermethylation to be assocaited with a better prognosis for HCC patients (HR= 0.089, 95%CI = 0.013-0.578; P = 0.012). Our findings showed that RASSF1A promoter hypermethylation occurs frequently, and may serve as a good prognostic factor.Item Ubiquitin-specific protease 14 expression associated with intrahepatic cholangiocarcinoma cell differentiation(Asian Pacific Organization for Cancer Prevention, 2011) Ubol Chuensumran; Pensri Saelee; Phaibul Punyarit; Sopit Wongkham; Chawalit Pairojkul; Siri Chauin; Songsak Petmitr; U. Chuensumran; Department of Chemistry, Faculty of Science and Technology, Rajabhat University Suan Dusit, Thailand; email: ubol_c@yahoo.comThe purpose of this study was to identify the gene alterations amplified from AO16 primer and examine whether the expression patterns of USP14 in clinical specimens from patients with intrahepatic cholangiocarcinoma (ICC) is associated with cancer cells. DNA from tumor and corresponding normal tissues of 52 patients was amplified with 33 arbitrary primers. The DNA fragment that altered most frequently in ICC was cloned, sequenced, and identified by comparison with known nucleotide sequences in the genome database. The DNA copy numbers of the allelic alterations in cholangiocarcinoma were determined by quantitative real-time PCR and interpreted as allelic loss or DNA amplification by comparison with the reference gene. Associations between allelic imbalance and clinicopathological parameters of ICC patients were evaluated by _2-tests. The Kaplan-Meier method was used to analyze survival rates. Immunohistochemically, USP14 showed weak cytoplasmic staining in normal bile duct epithelial cells. It was strongly detected in 21 cancer patients (43.8%). There were correlations between USP14 expression level and the clinicopathological features of ICC, histological grade (P < 0.05). However, there were no significant differences in age, gender, tumor size, metastasis, lymph node metastasis, and staging. USP14 expression was related to cholangiocarcinoma cell differentiation. Due to their emerging role in control of multiple signaling pathways and oncoproteins, USP14 inhibitors may be useful for anticancer agents.